How to buy Biocept stock

Biocept, Inc is a diagnostics & research business based in the US. Biocept shares (BIOC) are listed on the NASDAQ and all prices are listed in US Dollars. Biocept employs 104 staff and has a trailing 12-month revenue of around 0.00.

Biocept share price

Use our graph to track the performance of BIOC stocks over time.

Biocept shares at a glance

• Key figures

Information last updated 2021-05-08.

52-week range	$3.46 - $11.70
50-day moving average	$4.83
200-day moving average	$5.29
Wall St. target price	$12.00
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-2.63

Buy Biocept shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Biocept stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Biocept, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Biocept financials

Revenue TTM	$27.5 million
Gross profit TTM	$6.1 million
Return on assets TTM	-29.66%
Return on equity TTM	-102.07%
Profit margin	-64.84%
Book value	$1.77
Market capitalisation	$61.7 million

TTM: trailing 12 months

Shorting Biocept shares

There are currently 774,725 Biocept shares held short by investors – that's known as Biocept's "short interest". This figure is 12.5% down from 885,552 last month.

There are a few different ways that this level of interest in shorting Biocept shares can be evaluated.

Biocept's "short interest ratio" (SIR)

Biocept's "short interest ratio" (SIR) is the quantity of Biocept shares currently shorted divided by the average quantity of Biocept shares traded daily (recently around 629857.72357724). Biocept's SIR currently stands at 1.23. In other words for every 100,000 Biocept shares traded daily on the market, roughly 1230 shares are currently held short.

However Biocept's short interest can also be evaluated against the total number of Biocept shares, or, against the total number of tradable Biocept shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Biocept's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Biocept shares in existence, roughly 60 shares are currently held short) or 0.0578% of the tradable shares (for every 100,000 tradable Biocept shares, roughly 58 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Biocept.

Find out more about how you can short Biocept stock.

Biocept share dividends

We're not expecting Biocept to pay a dividend over the next 12 months.

Have Biocept's shares ever split?

Biocept's shares were split on a 1:10 basis on 7 September 2020. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Biocept shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Biocept shares which in turn could have impacted Biocept's share price.

Biocept share price volatility

Over the last 12 months, Biocept's shares have ranged in value from as little as $3.46 up to $11.7. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Biocept's is 0.7973. This would suggest that Biocept's shares are less volatile than average (for this exchange).

Biocept overview

Biocept, Inc. , an early stage molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell and circulating tumor nucleic acid assays utilizing a standard blood sample. Its cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring in order to identify resistance mechanisms. The company offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer, gastric cancer, colorectal cancer, prostate cancer, melanoma, pancreaticobiliary cancer, and ovarian cancer. Its Target-Selector molecular technology enables detection of mutations and genome alterations with enhanced sensitivity and specificity, as well as is applicable to nucleic acid from circulating tumor DNA; and Target-Selector CTC and molecular platforms provide biomarker detection and monitoring capabilities. In addition, it offers laboratory services to medical oncologists, neuro-oncologists, surgical oncologists, urologists, pulmonologists, pathologists, and other physicians. Further, it is developing PCR-based assays for detecting the COVID-19 virus.

Frequently asked questions

• What percentage of Biocept is owned by insiders or institutions?

  Currently 0.017% of Biocept shares are held by insiders and 10.858% by institutions.

• How many people work for Biocept?

  Latest data suggests 104 work at Biocept.

• When does the fiscal year end for Biocept?

  Biocept's fiscal year ends in December.

• Where is Biocept based?

  Biocept's address is: 9955 Mesa Rim Road, San Diego, CA, United States, 92121

• What is Biocept's ISIN number?

  Biocept's international securities identification number is: US09072V5012

• What is Biocept's CUSIP number?

  Biocept's Committee on Uniform Securities Identification Procedures number is: 09072V105